We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,686 | 16:35:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.57 | 188.01B |
From May 2019 to May 2024
Two Japanese studies Thursday showed AstraZeneca PLC's (AZN.LN) cancer drug Iressa provided significant advantages over types of chemotherapy for patients with a genetic mutation.
Data from the WJTOG 3405 and NEJ002 studies presented at a joint congress of the European Cancer Organisation and the European Society for Medical Oncology in Berlin showed Iressa extended the time patients lived without their cancer getting worse compared to chemotherapy in lung cancer patients with a specific mutation in the epidermal growth factor receptor gene.
One trial tested Iressa against cisplatin and docetaxel and the second compared it with carboplatin and paclitaxel.
AstraZeneca Medical Science Director Alison Armour said it is essential that testing for this mutation becomes part of standard clinical practice.
Iressa was approved in Europe in July for use in lung cancer patients with the mutation.
Company Web site: www.asrtrazeneca.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
